But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
But with the obvious buyer, Bristol, having apparently been outbid, there might be questions over Acceleron’s takeout price.
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
Meanwhile long-term efficacy of the Pfizer and Moderna jabs largely holds up, though J&J’s data seems less convincing.